Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
Status:
Completed
Trial end date:
2016-06-14
Target enrollment:
Participant gender:
Summary
The main objective of the current trial is to investigate safety, tolerability,
pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4
weeks in patients with COPD.